跳至主要内容
临床试验/EUCTR2013-003741-42-AT
EUCTR2013-003741-42-AT进行中(未招募)1 期

PROSPECTIVE STUDY OF [68GA]NODAGA-RGD-PET FOR THE DIAGNOSIS OF HEPATOCELLULAR CARCINOMA AND THE ASSESSMENT OF TREATMENT RESPONSE

Medizinische Universität Innsbruck, Abteilung für Nuklearmedizin0 个研究点目标入组 30 人开始时间: 2014年3月6日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Yet untreated HCC due to liver cirrhosis Child Pugh class A or class B. The diagnosis of HCC hast to be confirmed by multiphasic CT or MRI according to EASL/EORTC guidelines.
  • Written informed consent
  • Age 18 or above
  • In women, pregnancy must be excluded and contraception must be performed
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 30
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 30

排除标准

  • Decompensated liver cirrhosis Child Pugh class C
  • Uncontrolled complications of portal hypertension (refractory ascites, advanced hepatic encephalopathy or large esophageal varices)
  • Advanced renal insufficiency with an eGFR below 30 ml/min

研究者

发起方
Medizinische Universität Innsbruck, Abteilung für Nuklearmedizin

相似试验